A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Leukemia

Interventions

DRUG: Bleximenib

Sponsor

Janssen Research & Development, LLC